Cargando…
Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study [Expression of concern] [Erratum]
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Dove
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234872/ https://www.ncbi.nlm.nih.gov/pubmed/32494156 http://dx.doi.org/10.2147/OTT.S260688 |
| _version_ | 1783535860297236480 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7234872 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Dove |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-72348722020-06-02 Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study [Expression of concern] [Erratum] Onco Targets Ther Erratum Dove 2020-05-12 /pmc/articles/PMC7234872/ /pubmed/32494156 http://dx.doi.org/10.2147/OTT.S260688 Text en © 2020 Dove Medical Press. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
| spellingShingle | Erratum Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study [Expression of concern] [Erratum] |
| title | Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study [Expression of concern] [Erratum] |
| title_full | Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study [Expression of concern] [Erratum] |
| title_fullStr | Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study [Expression of concern] [Erratum] |
| title_full_unstemmed | Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study [Expression of concern] [Erratum] |
| title_short | Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study [Expression of concern] [Erratum] |
| title_sort | efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the milan criteria: a preliminary study [expression of concern] [erratum] |
| topic | Erratum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234872/ https://www.ncbi.nlm.nih.gov/pubmed/32494156 http://dx.doi.org/10.2147/OTT.S260688 |